Skip main navigation
Close Drawer MenuOpen Drawer Menu
Books

The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Back to table of contents
No Access

Chapter 13.Fluvoxamine

Edited by:
https://doi.org/10.1176/appi.books.9781615371624.as13

Sections

Structure–Activity Relations | Mechanism of Action | Pharmacological Profile | Pharmacokinetics and Disposition | Indications and Efficacy | Side Effects and Toxicology | Drug–Drug Interactions | Use in Pregnancy and Lactation | Conclusion | References

Excerpt

Fluvoxamine is a member of the selective serotonin reuptake inhibitor (SSRI) family of drugs. Initially manufactured by Duphar Laboratories in the United Kingdom in 1971, fluvoxamine was registered as an antidepressant in Switzerland in 1983, becoming the first drug in the now hugely popular SSRI class to reach the market. Since its introduction, fluvoxamine has undergone a wide range of trials to assess its therapeutic potential in depression, several anxiety disorders, and obsessive-compulsive disorder (OCD). Fluvoxamine has been available in the United States since 1994, when it received U.S. Food and Drug Administration (FDA) approval for the treatment of OCD (Ware 1997). More than 28 million people worldwide have been treated with fluvoxamine (Buchberger and Wagner 2002).

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.
  • Institutional Login
  • Sign in via OpenAthens
  • Register for access

  • Please login/register if you wish to pair your device and check access availability.

    Not a subscriber?

    Subscribe Now / Learn More

    PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

    Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).